

Growth Factors Market to Reach \$4.07 Billion by 2033 | Driven by Regenerative Medicine & Oncology | DataM Intelligence

Growth Factors Market size reached \$2.19 Billion in 2024 and will hit \$4.07 Billion by 2033, growing at 7.1% CAGR, fueled by oncology & biotech.

AUSTIN, TX, UNITED STATES,
September 19, 2025 /

EINPresswire.com/ -- According to DataM Intelligence, the [growth factors market](#) size reached US\$ 2.06 billion and rose to US\$ 2.19 billion in 2024. It is expected to reach US\$ 4.07 billion by

2033, growing at a CAGR of 7.1% during the forecast period 2025–2033. The Growth Factors Market has been witnessing significant expansion over the past decade, driven by advances in biotechnology, regenerative medicine, and oncology research. Growth factors are naturally occurring proteins that regulate crucial cellular processes such as proliferation, differentiation,

“


North America leads the Growth Factors Market, but Asia-Pacific will record the fastest CAGR, fueled by pharma expansion in China & India.”

DataM Intelligence

wound healing, and angiogenesis. With applications in stem cell therapy, tissue engineering, and cancer treatment, their adoption in healthcare and pharmaceutical industries continues to accelerate.

The market is primarily fueled by the increasing prevalence of chronic diseases such as cancer, diabetes, and cardiovascular disorders, where growth factors are used to enhance tissue repair and regeneration. The oncology segment dominates the market due to the extensive use of

growth factors in cancer therapeutics, particularly granulocyte colony-stimulating factors (G-CSF) for neutropenia management. Geographically, North America leads the market, supported by advanced healthcare infrastructure, strong biotechnology research, and high investment in clinical trials. Meanwhile, Asia-Pacific is anticipated to register the fastest growth, driven by rising healthcare expenditure and expanding pharmaceutical manufacturing capabilities in countries



like China and India.

Download Sample Report: <https://www.datamintelligence.com/download-sample/growth-factors-market>

Key Highlights from the Report:

- The global Growth Factors Market reached US\$ 2.19 billion in 2024 and is projected to hit US\$ 4.07 billion by 2033.
- The market is growing at a CAGR of 7.1% during 2025–2033, according to DataM Intelligence.
- Oncology remains the leading application segment due to the widespread use of growth factors in cancer therapy.
- North America dominates the global market, while Asia-Pacific shows the fastest growth trajectory.
- Recombinant growth factors account for the largest product share owing to their widespread use in biologics.
- Increasing investments in regenerative medicine and tissue engineering are accelerating demand.

Recent Developments:

United States:

1. In August 2025, US nuclear fusion companies like Commonwealth Fusion Systems, Helion Energy, and TAE Technologies secured large-scale private investment from Big Tech players, aiming to have pilot plants operational by 2030-2035.
2. In September 2025, robotics startup Figure raised over \$1 billion in a Series C round, bringing its valuation to ~\$39 billion. The funding will accelerate humanoid robot development & AI infrastructure.
3. In H1 2025, growth equity fundraising in the US jumped ~2.6× YoY for VC-companies raising \$100M+, totaling ~\$121 billion already exceeding the full-year 2024 total of \$111B. AI businesses captured ~62% of those funds.
4. In mid-2025, the US venture capital market saw more selective investments: fewer deals but much larger dollars per deal, especially in later-stage firms with demonstrated scalability & lower risk.

Japan:

1. In May 2025, an economic advisory panel in Japan recommended a \$400 billion (¥60 trillion) investment over 5 years to boost SME productivity through digitization, automation, and

encouraging consolidation.

2. In early September 2025, Mitsubishi UFJ Financial Group (MUFG) launched a ¥100 billion (~US\$680 million) real estate fund targeting underperforming mid-sized offices, residences, and hotels in Tokyo, Osaka, and Nagoya.

3. In Q2 2025, SoftBank Group saw a strong financial turnaround with profit of ¥421.8 billion (≈ US\$2.9B) for April-June, driven by its AI-investments and gains in its holdings like Nvidia and OpenAI.

4. In the semiconductor sector: Japan Advanced Semiconductor Manufacturing (JASM) is scaling its Phase-1 fab (12/16nm etc.) in Kumamoto, and Phase-2 (6nm) is being constructed to meet rising demand especially for automotive & image sensor applications.

Company Insights

Key players operating in the global Growth Factors Market include:

- Thermo Fisher Scientific Inc.
- F. Hoffmann-La Roche Ltd.
- Amgen Inc.
- Biocon Limited
- Novartis AG
- GenScript Biotech Corporation
- Bio-Techne Corporation
- Merck KGaA
- PeproTech, Inc.
- AbbVie Inc.

Market Segmentation:

The Growth Factors Market can be segmented based on product type, application, and end-user.

On the basis of product type, recombinant growth factors dominate the market as they are widely used in biologics and biosimilars production. These include vascular endothelial growth factor (VEGF), epidermal growth factor (EGF), platelet-derived growth factor (PDGF), and nerve growth factor (NGF). Natural growth factors also hold a significant share, particularly in wound healing and dermatological applications.

By application, oncology leads the market due to the high prevalence of cancer and the critical role of G-CSF and granulocyte-macrophage colony-stimulating factors (GM-CSF) in managing chemotherapy-induced neutropenia. Regenerative medicine, including stem cell therapy and tissue engineering, is another rapidly growing segment. Growth factors are also widely applied in

orthopedic, cardiovascular, and ophthalmic treatments.

In terms of end-users, hospitals and specialty clinics account for the largest share, driven by the growing use of growth factor-based therapies for complex diseases. Research institutes and biopharmaceutical companies also contribute significantly, focusing on drug discovery and therapeutic innovations.

Looking For A Detailed Full Report? Get it here: <https://www.datamintelligence.com/buy-now-page?report=growth-factors-market>

Regional Insights

The North American market remains the largest, attributed to high R&D expenditure, robust biotechnology infrastructure, and a large number of clinical trials focused on growth factor-based therapies. The U.S. leads in adoption due to FDA approvals and widespread use in oncology and regenerative medicine.

Europe also represents a major market, particularly countries like Germany, the UK, and France, where investments in biopharmaceutical innovation and collaborations with academic institutions drive demand.

The Asia-Pacific region is projected to grow at the fastest CAGR during the forecast period. Factors fueling this growth include expanding pharmaceutical production in China and India, rising government funding for healthcare, and increasing awareness of advanced therapeutic solutions. Japan and South Korea also play vital roles due to their technological advancements in biologics manufacturing.

Meanwhile, Latin America and the Middle East & Africa show steady growth potential, supported by improving healthcare access and rising investments in oncology and biosimilars.

Market Dynamics:

Market Drivers

The market is driven by the rising prevalence of chronic and lifestyle-related diseases such as cancer, cardiovascular disorders, and diabetes. Growth factors play a key role in disease management by enhancing tissue regeneration and cellular repair. Additionally, increasing investments in biotechnology and regenerative medicine, including stem cell therapy, are boosting adoption. The availability of recombinant growth factors and biosimilars also enhances accessibility and affordability, supporting overall market expansion.

Market Restraints

Despite strong growth potential, the market faces challenges such as the high cost of therapy, stringent regulatory requirements, and the risk of adverse side effects associated with growth

factor use. Moreover, the complexity of large-scale manufacturing and storage of biologics presents barriers for smaller companies. Patent expirations of leading products also create pricing pressures due to generic competition.

Market Opportunities

Significant opportunities lie in personalized medicine, where growth factors can be tailored to patient-specific needs for targeted therapies. Expanding applications in wound healing, orthopedics, and ophthalmology further broaden the market scope. Emerging economies with rapidly expanding healthcare infrastructure, such as India, China, and Brazil, present untapped potential. Moreover, ongoing advances in protein engineering and nanotechnology are likely to open new pathways for innovation in growth factor-based therapeutics.

Get Customization in the report as per your requirements:

<https://www.datamintelligence.com/customize/growth-factors-market>

Reasons to Buy the Report

- Comprehensive coverage of current and emerging growth factor therapies.
- Detailed market segmentation with insights into high-growth regions and applications.
- In-depth analysis of market drivers, restraints, and opportunities.
- Profiles of leading players with recent developments and strategies.
- Forecast data to support strategic decision-making through 2033.

Frequently Asked Questions (FAQs)

- How big is the Global Growth Factors Market in 2024 and what is its forecast for 2033?
- Who are the key players in the Growth Factors Market worldwide?
- What is the projected growth rate of the market during 2025–2033?
- Which region is estimated to dominate the industry through the forecast period?
- What are the major applications driving demand in the Growth Factors Market?

Conclusion

The Growth Factors Market is set for strong growth, expected to nearly double in value from US\$ 2.19 billion in 2024 to US\$ 4.07 billion by 2033. This growth is fueled by rising demand for regenerative therapies, increasing cancer prevalence, and technological advancements in biotechnology. While high costs and regulatory hurdles pose challenges, the future remains promising due to biosimilar development, expanding healthcare infrastructure in emerging economies, and continuous innovation in biologics. With strong support from industry leaders and expanding clinical applications, growth factors are poised to play a transformative role in the future of global healthcare.

Request for 2 Days FREE Trial Access: <https://www.datamintelligence.com/reports-subscription>

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

Competitive Landscape

Sustainability Impact Analysis

KOL / Stakeholder Insights

Unmet Needs & Positioning, Pricing & Market Access Snapshots

Market Volatility & Emerging Risks Analysis

Quarterly Industry Report Updated

Live Market & Pricing Trends

Import-Export Data Monitoring

Have a look at our Subscription Dashboard: <https://www.youtube.com/watch?v=x5oEiqEqTWg>

Related Reports:

[Epidermal Growth Factors \(EGFs\) Market](#)

[Fibroblast Growth Factors \(FGFs\) Market](#)

Sai Kiran

DataM Intelligence 4Market Research

+1 877-441-4866

[email us here](#)

Visit us on social media:

[LinkedIn](#)

[X](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/850593095>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.